-+ 0.00%
-+ 0.00%
-+ 0.00%

Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est

Benzinga·09/16/2026 12:56:53
语音播报
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.